NEONC Highlights Glioblastoma Drug Neo100 Ahead of BTIG Biotech Conference – NTHI Oncology Update

For biotech investors and oncology innovators: NEONC Technologies Holdings Inc. (OTC: NTHI), a clinical-stage company focused on CNS and brain cancer therapies, is set to present at the BTIG Virtual Biotech Conference on August 5–6.

In this NewsOut episode, Ana Berry shares how NEONC CEO Michael Reynolds will spotlight Neo100, a patented formulation of perillyl alcohol currently in clinical trials for glioblastoma. As NEONC expands visibility with institutional investors, this marks a pivotal moment in advancing new treatments for aggressive, underserved cancers.

🧠 Targeting glioblastoma & CNS cancers
💊 Neo100: Patented perillyl alcohol therapy
📅 BTIG Biotech Conference: Aug 5–6
📈 Investor meetings with CEO Michael Reynolds
📊 OTC: NTHI — Clinical-stage oncology

🏷️ Tags:
#NEONC
#NTHI
#Neo100
#Glioblastoma
#BrainCancerTreatment
#CNSOncology
#BiotechInvesting
#BTIGBiotechConference
#ClinicalTrials
#OncologyInnovation
#CancerResearch
#PerillylAlcohol
#MichaelReynolds
#NewsOut
#AnaBerry
#CancerTherapy